The anomalous pharmacology of fentanyl.

Eamonn Kelly, Katy Sutcliffe, Damiana Cavallo, Nokomis Ramos-Gonzalez, Norah Alhosan, Graeme Henderson

British journal of pharmacology 2023 Apr

filter terms:

Fentanyl is a key therapeutic, used in anaesthesia and pain management. It is also increasingly used illicitly and is responsible for a large and growing number of opioid overdose deaths, especially in North America. A number of factors have been suggested to contribute to fentanyl's lethality, including rapid onset of action, in vivo potency, ligand bias, induction of muscle rigidity and reduced sensitivity to reversal by naloxone. Some of these factors can be considered to represent 'anomalous' pharmacological properties of fentanyl when compared with prototypical opioid agonists such as morphine. In this review, we examine the nature of fentanyl's 'anomalous' properties, to determine whether there is really a pharmacological basis to support the existence of such properties, and also discuss whether such properties are likely to contribute to overdose deaths involving fentanyls. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc. © 2021 The British Pharmacological Society.

Citation

Eamonn Kelly, Katy Sutcliffe, Damiana Cavallo, Nokomis Ramos-Gonzalez, Norah Alhosan, Graeme Henderson. The anomalous pharmacology of fentanyl. British journal of pharmacology. 2023 Apr;180(7):797-812